



## **Sol-Gel to Present at Upcoming Healthcare Investor Conferences in September**

September 8, 2020

NESS ZIONA, Israel, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies (NASDAQ: SLGL), ("Sol-Gel"), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the company will present at the following upcoming virtual investor conferences.

Dr. Alon Seri-Levy, Sol-Gel's Chief Executive Officer, will provide an overview of the Company and give a business update. A live webcast of the presentation will be available under the "Events and Presentations" in the investors section of the Company's website at [www.sol-gel.com](http://www.sol-gel.com). An archived webcast recording of the event will be available on the website for approximately 30 days.

### **H.C. Wainwright Healthcare Conference**

Speaker: Gilad Mamlok, Chief Financial Officer  
Date: September 15, 2020  
Time: 10:00 AM ET

### **Cantor Fitzgerald Virtual Global Healthcare Conference – Fireside Chat**

Speakers: Dr. Alon Seri-Levy, Chief Executive Officer  
Gilad Mamlok, Chief Financial Officer  
John Vieira, U.S. Head of Commercialization  
Date: September 17, 2020  
Time: 8:40 AM ET

### **About Sol-Gel Technologies**

Sol-Gel is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel leverages its proprietary microencapsulation technology platform for Twynéo, for the treatment of acne vulgaris, and Epsolay, for the treatment of papulopustular rosacea. The Company's pipeline also includes SGT-210, an early-stage topical epidermal growth factor receptor inhibitor, erlotinib, for the treatment of punctate palmoplantar keratoderma, and preclinical assets tapinarof and roflumilast. For additional information, please visit [www.sol-gel.com](http://www.sol-gel.com).

### **For further information, please contact:**

Sol-Gel Contact:  
Gilad Mamlok  
Chief Financial Officer  
+972-8-9313433

Investor Contact:  
Lee Stern  
Solebury Trout  
+1-917-312-5998  
[lsfern@soleburytrout.com](mailto:lsfern@soleburytrout.com)

Source: Sol-Gel Technologies Ltd.



Source: Sol-Gel Technologies Ltd.